Optical molecular imaging of multiple Biomarkers of epithelial neoplasia: Epidermal growth factor receptor expression and metabolic activity in oral mucosa1

Translational Oncology

Volumn 5, Issue 3, 2012, Pages 160-171

  Rosbach, Kelsey J ^a   Williams, Michelle D ^b   Gillenwater, Ann M ^b   Richards Kortum, Rebecca R ^a  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; EX VIVO STUDY; FLUORESCENCE IMAGING; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; METABOLISM; MOLECULAR IMAGING; MOUTH MUCOSA; MOUTH TUMOR; PERSONALIZED MEDICINE; PROTEIN EXPRESSION;

EID: 84862023615     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11310     Document Type: Article

References (53)

1. Lippman SM and Hong WK (2001). Molecular markers of the risk of oral cancer. N Engl J Med 344, 1323-1326.
2. Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Shah JS, Jetly DH, Kobawala TP, Patel KC, Shukla SN, Shah PM, et al. (2007). Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 22, 132-143.
3. Mashberg A and Samit AM (1989). Early detection, diagnosis, and management of oral and oropharyngeal cancer. CA Cancer J Clin 39, 67-88.
4. Braakhuis BJ, Leemans CR, and Brakenhoff RH (2004). A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med 33, 317-322.
5. Ludwig JA and Weinstein JN (2005). Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5, 845-856.
6. Hornick JL and Fletcher CD (2007). The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38, 679-687.
7. Hsiung PL, Hardy J, Friedland S, Soetikno R, Du CB, Wu AP, Sahbaie P, Crawford JM, Lowe AW, Contag CH, et al. (2008). Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 14, 454-458.
8. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, and Storkel S (2004). Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52, 893-901.
9. Themelis G, Yoo JS, and Ntziachristos V (2008). Multispectral imaging using multiple-bandpass filters. Opt Lett 33, 1023-1025.
10. Mydlarz WK, Hennessey PT, and Califano JA (2010). Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opin Med Diagn 4, 53-65.
11. Lippman SM, Sudbo J, and Hong WK (2005). Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23, 346-356.
12. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, et al. (2010). Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 3, 800-809.
13. Shin DM, Ro JY, Hong WK, and Hittelman WN (1994). Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54, 3153-3159.
14. Rubin Grandis J, Melhem MF, Barnes EL, and Tweardy DJ (1996). Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78, 1284-1292.
15. Srinivasan M and Jewell SD (2001). Evaluation of TGF-α and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oncology 61, 284-292.
16. Kannan S, Chandran GJ, Balaram P, Chidambaram S, and Nair MK (1996). Potential biological markers for the staging of tumor progression in oral mucosa: a multivariate analysis. Int J Biol Markers 11, 67-76.
17. Mellanen P, Minn H, Grenman R, and Harkonen P (1994). Expression of glucose transporters in head-and-neck tumors. Int J Cancer 56, 622-629.
18. Kunkel M, Moergel M, Stockinger M, Jeong JH, Fritz G, Lehr HA, and Whiteside TL (2007). Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 43, 796-803.
19. Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenco SV, and Soares FA (2010). GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 15, 2374-2387.
20. Tian M, Zhang H, Nakasone Y, Mogi K, and Endo K (2004). Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 31, 5-12.
21. Ohba S, Fujii H, Ito S, Fujimaki M, Matsumoto F, Furukawa M, Yokoyama J, Kusunoki T, Ikeda K, and Hino O (2010). Overexpression of GLUT-1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis. J Oral Pathol Med 39, 74-78.
22. Nitin N, Rosbach KJ, El-Naggar A, Williams M, Gillenwater A, and Richards-Kortum RR (2009). Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia 11, 542-551.
23. O'Neil RG, Wu L, and Mullani N (2005). Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol 7, 388-392.
24. Sheth RA, Josephson L, and Mahmood U (2009). Evaluation and clinically relevant applications of a fluorescent imaging analog to fluorodeoxyglucose positron emission tomography. J Biomed Opt 14, 064014.
25. Nitin N, Carlson AL, Muldoon T, El-Naggar AK, Gillenwater A, and Richards-Kortum R (2009). Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. Int J Cancer 124, 2634-2642.
26. Roblyer D, Richards-Kortum R, Sokolov K, El-Naggar AK, Williams MD, Kurachi C, and Gillenwater AM (2008). Multispectral optical imaging device for in vivo detection of oral neoplasia. J Biomed Opt 13, 024019.
27. 18F]fluoro-2-deoxy-D-glucose accumulation in positron emission tomography. Br J Oral Maxillofac Surg 46, 180-186.
28. Shanks N, Greek R, and Greek J (2009). Are animal models predictive for humans? Philos Ethics Humanit Med 4, 2.
29. Roblyer D, Kurachi C, Stepanek V, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, and Richards-Kortum R (2009). Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res 2, 423-431.
30. Roblyer D, Kurachi C, Stepanek V, Schwarz RA, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, and Richards-Kortum R (2010). Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. J Biomed Opt 15, 066017.
31. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, et al. (2010). Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc 141, 509-520.
32. Rubin Grandis J, Tweardy DJ, and Melhem MF (1998). Asynchronous modulation of transforming growth factor α and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 4, 13-20.
33. Carlson AL, Gillenwater AM, Williams MD, El-Naggar AK, and Richards-Kortum RR (2007). Confocal microscopy and molecular-specific optical contrast agents for the detection of oral neoplasia. Technol Cancer Res Treat 6, 361-374.
34. Modjtahedi H and Essapen S (2009). Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20, 851-855.
35. Rogers SJ, Box C, Chambers P, Barbachano Y, Nutting CM, Rhys-Evans P, Workman P, Harrington KJ, and Eccles SA (2009). Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J Pathol 218, 122-130.
36. Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, et al. (2009). Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci 2, 183-192.
37. Sharafinski ME, Ferris RL, Ferrone S, and Grandis JR (2010). Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32, 1412-1421.
38. Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, and Ferlito A (2008). Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30, 800-809.
39. Kondo N, Tsukuda M, Ishiguro Y, Kimura M, Fujita K, Sakakibara A, Takahashi H, Toth G, and Matsuda H (2010). Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 23, 957-963.
40. Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, and Nair P (2010). Nimotuzumab with chemoradiation confers a survival advantage in treatmentnaive head and neck tumors over expressing EGFR. Cancer Biol Ther 10, 673-681.
41. Williams MD (2010). Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol 4, 62-69.
42. Prado SM, Cedrun JL, Rey RL, Villaamil VM, Garcia AA, Ayerbes MV, and Aparicio LA (2010). Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias. Exp Mol Pathol 89, 197-203.
43. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, and Wilson GD (2005). Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23, 5560-5567.
44. Suwinski R, Jaworska M, Nikiel B, Grzegorz W, Bankowska-Wozniak M, Wojciech M, Krzysztof S, and Dariusz L (2010). Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial. Int J Radiat Oncol Biol Phys 77, 438-446.
45. Scarfone C, Lavely WC, Cmelak AJ, Delbeke D, Martin WH, Billheimer D, and Hallahan DE (2004). Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 45, 543-552.
46. Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, and Schwaiger M (2009). Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol 2009, 208725.
47. Martin RC, Fulham M, Shannon KF, Hughes C, Gao K, Milross C, Tin MM, Jackson M, Clifford A, Boyer MJ, et al. (2009). Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head Neck 31, 244-250.
48. 18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Clin Cancer Res 16, 4434-4445.
49. 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging 37, 1318-1327.
50. de Bree R, van der Putten L, Brouwer J, Castelijns JA, Hoekstra OS, and Leemans CR (2009). Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncol 45, 386-393.
51. Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, Massey BL, Blumin J, Wilson JF, and Wang D (2011). Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer. Int J Radiat Oncol Biol Phys 81, e825-e832.
52. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, and Nyati MK (2010). Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70, 2862-2869.
53. Nouri AM, Thompson C, Cannell H, Symes M, Purkiss S, and Amirghofran Z (2000). Profile of epidermal growth factor receptor (EGFR) expression in human malignancies: effects of exposure to EGF and its biological influence on established human tumour cell lines. Int J Mol Med 6, 495-500.